propafenone has been researched along with Tachycardia, Supraventricular in 73 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Tachycardia, Supraventricular: A generic expression for any tachycardia that originates above the BUNDLE OF HIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind, placebo-controlled trial of the efficacy and tolerability of propafenone was undertaken in 100 patients with paroxysmal supraventricular tachycardia ([PSVT] n = 52) or atrial fibrillation/flutter ([PAF] n = 48) who had recorded two or more symptomatic arrhythmia recurrences by transtelephonic ECG monitoring during a 3-month drug-free observation period." | 9.08 | A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. ( , 1995) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 9.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "We present our experience on the efficacy of propafenone in ten symptomatic patients with Wolff-Parkinson-White syndrome." | 9.06 | Propafenone in Wolff-Parkinson-White syndrome at risk. ( Chiariello, M; Condorelli, M; De Paola, M; Giasi, M; Santinelli, C; Santinelli, V; Smimmo, D; Turco, P, 1990) |
| "This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter." | 8.80 | Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. ( Rae, AP, 1998) |
| "The antiarrhythmic effect of oral propafenone was evaluated in 10 patients with Wolff-Parkinson-White syndrome presenting with non-ventricular arrhythmias (paroxysmal supraventricular tachycardia n = 7, atrial fibrillation or flutter n = 3)." | 7.68 | Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. ( Kallikazaros, I; Papoutsakis, P; Stefanadis, C; Vassiliadis, I, 1990) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 7.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "Propafenone was effective in suppressing recurrences of AF in 55." | 6.40 | Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. ( Antman, EM; Maisel, WH; Reimold, SC, 1998) |
| "Propafenone has comparatively few noncardiac side effects." | 6.39 | Propafenone: an effective agent for the management of supraventricular arrhythmias. ( Grant, AO, 1996) |
| "The presence of a congenital heart defect and the time of onset of the arrhythmias had a significant influence on the efficacy of propafenone." | 5.29 | Clinical experience with propafenone for cardiac arrhythmias in the young. ( Bourgeous, M; Heusch, A; Kramer, HH; Krogmann, ON; Rammos, S, 1994) |
| "Propafenone was given to 60 children (mean age 4." | 5.29 | The use of propafenone in the treatment of tachyarrhythmias in children. ( Figini, A; Mauri, L; Vignati, G, 1993) |
| "A double-blind, placebo-controlled trial of the efficacy and tolerability of propafenone was undertaken in 100 patients with paroxysmal supraventricular tachycardia ([PSVT] n = 52) or atrial fibrillation/flutter ([PAF] n = 48) who had recorded two or more symptomatic arrhythmia recurrences by transtelephonic ECG monitoring during a 3-month drug-free observation period." | 5.08 | A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. ( , 1995) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 5.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "We present our experience on the efficacy of propafenone in ten symptomatic patients with Wolff-Parkinson-White syndrome." | 5.06 | Propafenone in Wolff-Parkinson-White syndrome at risk. ( Chiariello, M; Condorelli, M; De Paola, M; Giasi, M; Santinelli, C; Santinelli, V; Smimmo, D; Turco, P, 1990) |
| "This review summarizes the results of placebo-controlled trials of propafenone, a class IC antiarrhythmic drug, in patients with supraventricular tachycardia, atrial fibrillation (AF), and atrial flutter." | 4.80 | Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias. ( Rae, AP, 1998) |
| " These antiarrhythmics, prescribed to prevent atrial fibrillation (3 patients) and atrial flutter (5 patients), were flecainide in 4 cases, propafenone in 2 cases and cibenzoline and hydroquinidine respectively associated with digitoxine and propranolol." | 4.79 | [Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications]. ( Aouate, P; Benassar, A; Fontaine, G; Frank, R; Jacquemin, M; Laborde, JP; Tageddine, R; Tonet, J; Turlure, A, 1995) |
| "The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD)." | 4.31 | Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. ( Alexander, ME; Bezzerides, VJ; DeWitt, ES; Dionne, A; Eberly, LM; Mah, DY; O'Leary, ET; Przybylski, R; Triedman, JK; Walsh, EP, 2023) |
| "To assess the efficacy of propafenone in prevention of atrioventricular nodal reentrant tachycardia (AVNRT) and orthodromic atrioventricular tachycardia (AVRT) based on the clinical results of arrhythmia recurrence and find the electrophysiological predictor of propafenone effectiveness." | 3.78 | Electrophysiological predictors of propafenone efficacy in prevention of atrioventricular nodal re-entrant and atrioventricular re-entrant tachycardia. ( Babić, Z; Bosnjak, H; Pavlović, N; Petrac, D; Pintarić, H; Vrsalović, M; Zeljković, I, 2012) |
| " The tachycardia was felt to be focal atrial fibrillation, and the patient was placed on propafenone with good results." | 3.71 | Paroxysmal supraventricular tachycardia induced by oral stimulation: a case report and review of swallow-induced dysrhythmias. ( Chock, JG; Gill, MR, 2002) |
| " After 24-hour Holter ECG monitoring had revealed Wolff-Parkinson-White syndrome as cause of the PSVT, propafenone was administered (15 mg/kg daily) and has prevented further recurrence of the tachycardia." | 3.69 | [Adenosine triphosphate for supraventricular tachycardia in newborns and suckling infants]. ( Gessler, P; Haas, NA; König, SA; Pufahl, C; Teufel, M, 1994) |
| "A 46 year-old woman with Wolff-Parkinson-White syndrome (postero-septal accessory pathway), symptomatic for recurrent episodes of nonsustained paroxismal supraventricular tachycardia (PSVT), was empirically treated with propafenone (600 mg/day)." | 3.68 | Opposite effects of propafenone and flecainide in a patient with reciprocating supraventricular tachycardia. ( Calvi, V; di Bona, G; Manzoli, U; Montenero, AS; Natale, A; Santarelli, P, 1990) |
| "The antiarrhythmic effect of oral propafenone was evaluated in 10 patients with Wolff-Parkinson-White syndrome presenting with non-ventricular arrhythmias (paroxysmal supraventricular tachycardia n = 7, atrial fibrillation or flutter n = 3)." | 3.68 | Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. ( Kallikazaros, I; Papoutsakis, P; Stefanadis, C; Vassiliadis, I, 1990) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 3.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "The trial includes septic shock patients with new-onset arrhythmia, but without severe impairment of the left ventricular ejection fraction." | 2.90 | Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study. ( Balik, M; Brestovansky, P; Brozek, T; Duska, F; Flaksa, M; Maly, M; Matousek, V; Otahal, M; Pazout, J; Porizka, M; Rulisek, J; Sachl, R; Smid, O; Stach, Z; Stritesky, M; Svobodova, E; Waldauf, P, 2019) |
| "With the dosage used in the present study, the efficacy on terminating PSVT was comparable between AHH and PRO." | 2.73 | [Efficacy of intravenous Acehytisine Hydrochloride versus propafenone on terminating paroxysmal supraventricular tachycardia: a double-blinded, randomized multi-center study]. ( Gao, X; Li, JD; Liu, JH; Yang, YM; Yang, ZM; Zhu, J, 2007) |
| " Three patients taking propafenone had serious treatment-related adverse effects that required drug discontinuation." | 2.70 | Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. ( Droszcz, W; Graff, O; Kawecka-Jaszcz, K; Kozlowski, JW; Krzeminska-Pakula, M; Kulakowski, P; Malolepszy, J; Ruzyllo, W; Swiatecka, G; Szechinski, J; Tendera, M; Wnuk-Wojnar, AM, 2001) |
| "An important issue regarding the long-term use of antiarrhythmic drugs concerns the safety of these agents, particularly with regard to cardiac toxicity." | 2.68 | Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. ( Anderson, JL; Podrid, PJ, 1996) |
| "ATP is an effective treatment of supraventricular tachycardia when the atrioventricular (AV) node is part of the reentrant circuit." | 2.67 | Action of ATP on ventricular automaticity. ( Bachernegg, M; Decrinis, M; Domanowits, H; Kickenweiz, E; Laggner, AN; Stark, G; Stark, U; Sterz, F; Tritthart, HA, 1994) |
| "The time to first recurrence was prolonged for the overall group of 23 patients while they received propafenone (P = 0." | 2.67 | Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. ( McCarthy, EA; Pritchett, EL; Wilkinson, WE, 1991) |
| "Propafenone, 2 mg/kg was given over 15 min and blood pressure and heart rate were monitored in the following hour." | 2.66 | [Efficacy of propafenone in supraventricular arrhythmias]. ( Ayala, A; Goich, J; Kauffmann, R; Manzur, F; Parra, C, 1989) |
| "Propafenone was effective in suppressing recurrences of AF in 55." | 2.40 | Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. ( Antman, EM; Maisel, WH; Reimold, SC, 1998) |
| "With flecainide, nine cases were reported at varying times after initiation of therapy, from in-hospital to 8 months." | 2.39 | Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. ( Prystowsky, EN, 1994) |
| "Propafenone has comparatively few noncardiac side effects." | 2.39 | Propafenone: an effective agent for the management of supraventricular arrhythmias. ( Grant, AO, 1996) |
| "Propafenone was discontinued in 7 infants due to widening of the QRS complex." | 1.72 | Antiarrhythmic Medication in Neonates and Infants with Supraventricular Tachycardia. ( Balmer, C; Bruder, D; Cavigelli-Brunner, A; Gass, M; Weber, R, 2022) |
| " Except for the dosage of noradrenaline (0." | 1.46 | Propafenone for supraventricular arrhythmias in septic shock-Comparison to amiodarone and metoprolol. ( Balik, M; Kolnikova, I; Kristof, J; Maly, M; Tavazzi, G; Waldauf, P, 2017) |
| "Propafenone has little effects on sinus node." | 1.30 | [The study of acute clinical electrophysiological effects of propafenone on paroxysmal supraventricular tachycardia using transesophageal atrial pacing technique]. ( Li, Q; Peng, D; Wang, Z, 1997) |
| "The presence of a congenital heart defect and the time of onset of the arrhythmias had a significant influence on the efficacy of propafenone." | 1.29 | Clinical experience with propafenone for cardiac arrhythmias in the young. ( Bourgeous, M; Heusch, A; Kramer, HH; Krogmann, ON; Rammos, S, 1994) |
| "Propafenone was given as a bolus injection of 1." | 1.29 | [Evaluation of the clinical acute electrophysiological effects of propafenone using transesophageal atrial pacing]. ( Cheng, X; He, F; Zhao, X, 1994) |
| "Propafenone has been efficient in preventing supraventricular tachycardias in all patients." | 1.29 | [Propafenone efficacy in preventing supraventricular tachycardia in childhood]. ( Barrenetxea, JI; Bodegas, A; Cabrera, A; Galdeano, JM; Idígoras, G; Pastor, E; Pérez García, P; Rumoroso, JR; Sarrionaindía, MJ; Sota, J, 1994) |
| "By treatment with propafenone, both patients showed dramatic and rapid improvement of symptoms and the left ventricular dysfunction." | 1.29 | Reversible left ventricular diastolic dysfunction resulting from frequent supraventricular tachycardia. ( Hasatani, K; Nakao, T; Okamoto, S; Shimizu, M; Takeda, R; Zenda, T, 1993) |
| " Five patients exhibited unexpected marked QRS complex prolongation (50 to 200%) despite low propafenone dosage (< 300 mg/m2/day) and level ranging from 0." | 1.29 | Usefulness of propafenone for supraventricular arrhythmias in infants and children. ( Janousek, J; Kallfelz, HC; Paul, T; Reimer, A, 1993) |
| "Propafenone was given to 60 children (mean age 4." | 1.29 | The use of propafenone in the treatment of tachyarrhythmias in children. ( Figini, A; Mauri, L; Vignati, G, 1993) |
| "Propafenone was tested in 13 patients (43." | 1.28 | [Electropharmacological test with class-I C drugs in paroxysmal supraventricular re-entrant tachycardia: is a negative result with a drug predictive of the ineffectiveness of other drugs of the same class?]. ( Braito, G; Furlanello, F; Guarnerio, M; Inama, G; Vergara, G, 1991) |
| " Adverse effects were encountered in 7 patients: in 1 case worsened arrhythmia and in 6 patients, with long-lasting arrhythmias, congestive heart failure." | 1.28 | [The emergency treatment of supraventricular tachyarrhythmias: the efficacy and safety of intravenous propafenone]. ( Annoni, P; Baroffio, R; Bossi, M; Cazzaniga, L; Ciaramella, C; Guzzini, F; Maestroni, A; Tisi, G, 1992) |
| "Propafenone was administered to 32 patients, with positive results in 15 (46." | 1.28 | Long-term follow-up of patients with inducible supraventricular tachycardia treated with flecainide or propafenone: therapy guided by transesophageal electropharmacologic testing. ( Bertoldi, A; Dallago, M; Del Greco, M; Furlanello, F; Guarnerio, M; Inama, G; Vergara, G, 1992) |
| "Propafenone terminated tachyarrhythmias in all patients during or within a few minutes after stopping infusion (mean conversion time: 6." | 1.28 | [Use of propafenone in emergency therapy]. ( Di Ieso, N; Guardascione, A; Liguori, A; Pellegrino, G; Piatto, A; Ruggiero, P; Scarnera, P, 1989) |
| "Thus propafenone can produce rate-dependent failure of ventricular capture which is associated with marked prolongation of refractoriness and QRS duration suggesting a marked use-dependent drug effect in selected patients." | 1.28 | Rate-dependent failure of ventricular capture in patients treated with oral propafenone. ( Almendral, J; Arenal, A; Delcan, JL; Josephson, ME; San Román, D; Soriano, J, 1992) |
| " In 11/12 patients responsive to oral propafenone the minimum effective dosage in preventing the induction of the arrhythmia was 600 mg/day." | 1.28 | Paroxysmal supraventricular tachycardia: experience with propafenone. ( Chiariello, M; De Paola, M; Santinelli, V; Smimmo, D; Turco, P, 1989) |
| " Propafenone controlled dysrhythmia very well in 4 out of the ten patients, and satisfactorily in another one at a dosage ranging from 450 to 900 mg/day in 3 or 4 divided doses; this result was documented using continuous 24 hr." | 1.28 | [Anti-arrhythmia efficacy of propafenone per os in the prevention of paroxysmal supraventricular arrhythmia resistant to class Ia agents]. ( Amiel, A; Boutaud, P; Ciber, M; Demange, J; Guillem, JP; Herpin, D; Maarek-Charbit, M, 1989) |
| "Propafenone was administered to 58 patients with a mean age of 3." | 1.28 | Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias. ( Kallfelz, HC; Paul, T; Reimer, A, 1991) |
| "Among them 29 cases with SVT (including WPW syndrome in 11, paroxysmal AF or Af in 3) and the other two cases were studied for other reasons." | 1.28 | [Electrophysiologic effects of intravenous propafenone]. ( Song, YC; Sun, RL; Zhang, S, 1989) |
| " The same holds true for general tolerance: in 2 cases drug administration is discontinued and 11 patients present neurologic and digestive troubles improving after lowering the dosage or increasing the fractionation." | 1.27 | [Injectable and oral propafenone in nodal reentry and pathways of ventricular preexcitation]. ( Cosnay, P; Fauchier, JP; Kapusta, P; Moquet, B; Rouesnel, P; Vrancea, F, 1986) |
| "Propafenone was administered during electrophysiologic testing to determine its efficacy and safety for terminating and preventing reinduction of paroxysmal supraventricular reentrant tachycardia." | 1.27 | Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. ( Gersh, BJ; Hammill, SC; Holmes, DR; McLaran, CJ; Osborn, MJ; Wood, DL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (23.29) | 18.7374 |
| 1990's | 39 (53.42) | 18.2507 |
| 2000's | 7 (9.59) | 29.6817 |
| 2010's | 7 (9.59) | 24.3611 |
| 2020's | 3 (4.11) | 2.80 |
| Authors | Studies |
|---|---|
| Bruder, D | 1 |
| Weber, R | 1 |
| Gass, M | 1 |
| Balmer, C | 1 |
| Cavigelli-Brunner, A | 1 |
| Przybylski, R | 1 |
| Eberly, LM | 1 |
| Alexander, ME | 1 |
| Bezzerides, VJ | 1 |
| DeWitt, ES | 1 |
| Dionne, A | 1 |
| Mah, DY | 1 |
| Triedman, JK | 1 |
| Walsh, EP | 1 |
| O'Leary, ET | 1 |
| Balik, M | 2 |
| Waldauf, P | 2 |
| Maly, M | 2 |
| Matousek, V | 1 |
| Brozek, T | 1 |
| Rulisek, J | 1 |
| Porizka, M | 1 |
| Sachl, R | 1 |
| Otahal, M | 1 |
| Brestovansky, P | 1 |
| Svobodova, E | 1 |
| Flaksa, M | 1 |
| Stach, Z | 1 |
| Pazout, J | 1 |
| Duska, F | 1 |
| Smid, O | 1 |
| Stritesky, M | 1 |
| Bergonti, M | 1 |
| Assanelli, E | 1 |
| Agostoni, P | 1 |
| Bjeloševič, M | 1 |
| Illíková, V | 1 |
| Tomko, J | 1 |
| Olejník, P | 1 |
| Chalupka, M | 1 |
| Hatala, R | 1 |
| Kolnikova, I | 1 |
| Tavazzi, G | 1 |
| Kristof, J | 1 |
| Doki, K | 1 |
| Shirayama, Y | 1 |
| Sekiguchi, Y | 1 |
| Aonuma, K | 1 |
| Kohda, Y | 1 |
| Homma, M | 1 |
| Mihálcz, A | 1 |
| Földesi, C | 1 |
| Kardos, A | 1 |
| Ladunga, K | 1 |
| Szili-Török, T | 1 |
| Chachua, T | 1 |
| Abuladze, G | 1 |
| Nebieridze, M | 1 |
| Pintarić, H | 1 |
| Zeljković, I | 1 |
| Babić, Z | 1 |
| Vrsalović, M | 1 |
| Pavlović, N | 1 |
| Bosnjak, H | 1 |
| Petrac, D | 1 |
| Flores Pérez, J | 1 |
| Ramírez Mendiola, B | 1 |
| Flores Pérez, C | 1 |
| García Álvarez, R | 1 |
| Juárez Olguín, H | 1 |
| Chock, JG | 1 |
| Gill, MR | 1 |
| Pavoni, D | 1 |
| Ragazzo, S | 1 |
| Driussi, M | 1 |
| Antonini-Canterin, F | 1 |
| Pavan, D | 1 |
| Zardo, F | 1 |
| Nicolosi, GL | 1 |
| Capella, GL | 1 |
| Wiesfeld, AC | 1 |
| Ansink, JM | 1 |
| van Veldhuisen, DJ | 1 |
| van Gelder, IC | 1 |
| Gao, X | 1 |
| Zhu, J | 1 |
| Yang, YM | 1 |
| Li, JD | 1 |
| Yang, ZM | 1 |
| Liu, JH | 1 |
| Heusch, A | 1 |
| Kramer, HH | 1 |
| Krogmann, ON | 1 |
| Rammos, S | 1 |
| Bourgeous, M | 1 |
| He, F | 1 |
| Zhao, X | 1 |
| Cheng, X | 1 |
| Stark, G | 1 |
| Domanowits, H | 1 |
| Sterz, F | 1 |
| Stark, U | 1 |
| Bachernegg, M | 1 |
| Kickenweiz, E | 1 |
| Decrinis, M | 1 |
| Laggner, AN | 1 |
| Tritthart, HA | 1 |
| Merrick, AF | 1 |
| Odom, NJ | 1 |
| Keenan, DJ | 1 |
| Grotte, GJ | 1 |
| Prystowsky, EN | 1 |
| Haas, NA | 1 |
| Pufahl, C | 1 |
| König, SA | 1 |
| Gessler, P | 1 |
| Teufel, M | 1 |
| Cobbe, SM | 1 |
| Bodegas, A | 1 |
| Cabrera, A | 1 |
| Sarrionaindía, MJ | 1 |
| Idígoras, G | 1 |
| Rumoroso, JR | 1 |
| Pérez García, P | 1 |
| Pastor, E | 1 |
| Galdeano, JM | 1 |
| Sota, J | 1 |
| Barrenetxea, JI | 1 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Manz, M | 2 |
| Lüderitz, B | 2 |
| Beaufort-Krol, GC | 1 |
| Bink-Boelkens, MT | 1 |
| Nakao, T | 1 |
| Hasatani, K | 1 |
| Okamoto, S | 1 |
| Zenda, T | 1 |
| Shimizu, M | 1 |
| Takeda, R | 1 |
| Mannino, MM | 1 |
| Mehta, D | 1 |
| Gomes, JA | 1 |
| Janousek, J | 1 |
| Paul, T | 2 |
| Reimer, A | 2 |
| Kallfelz, HC | 2 |
| Vignati, G | 1 |
| Mauri, L | 1 |
| Figini, A | 1 |
| Pritchett, EL | 2 |
| Wilkinson, WE | 2 |
| Clair, WK | 1 |
| McCarthy, EA | 2 |
| Chimienti, M | 1 |
| Cullen, MT | 1 |
| Casadei, G | 1 |
| Aouate, P | 1 |
| Frank, R | 1 |
| Fontaine, G | 1 |
| Tonet, J | 1 |
| Tageddine, R | 1 |
| Benassar, A | 1 |
| Turlure, A | 1 |
| Jacquemin, M | 1 |
| Laborde, JP | 1 |
| Candinas, R | 1 |
| Gloor, HO | 1 |
| Lindner, W | 1 |
| Ha, HR | 1 |
| Buchinger, W | 1 |
| Amann, FW | 1 |
| Follath, F | 1 |
| Podrid, PJ | 1 |
| Anderson, JL | 1 |
| Grant, AO | 1 |
| Fish, FA | 1 |
| Mehta, AV | 1 |
| Johns, JA | 1 |
| Mirone, L | 1 |
| Altomonte, L | 1 |
| Ferlisi, EM | 1 |
| Zoli, A | 1 |
| Magaró, M | 1 |
| Yu, WC | 1 |
| Chen, SA | 1 |
| Lee, SH | 1 |
| Tai, CT | 1 |
| Feng, AN | 1 |
| Kuo, BI | 1 |
| Ding, YA | 1 |
| Chang, MS | 1 |
| Rae, AP | 1 |
| Reimold, SC | 1 |
| Maisel, WH | 1 |
| Antman, EM | 1 |
| Müller, U | 1 |
| Jochheim, R | 1 |
| Knaup, W | 1 |
| Tenholt, M | 1 |
| Li, Q | 1 |
| Wang, Z | 1 |
| Peng, D | 1 |
| Tendera, M | 1 |
| Wnuk-Wojnar, AM | 1 |
| Kulakowski, P | 1 |
| Malolepszy, J | 1 |
| Kozlowski, JW | 1 |
| Krzeminska-Pakula, M | 1 |
| Szechinski, J | 1 |
| Droszcz, W | 1 |
| Kawecka-Jaszcz, K | 1 |
| Swiatecka, G | 1 |
| Ruzyllo, W | 1 |
| Graff, O | 1 |
| Tisi, G | 1 |
| Annoni, P | 1 |
| Baroffio, R | 1 |
| Cazzaniga, L | 1 |
| Ciaramella, C | 1 |
| Guzzini, F | 1 |
| Maestroni, A | 1 |
| Bossi, M | 1 |
| Furlanello, F | 2 |
| Guarnerio, M | 2 |
| Inama, G | 2 |
| Vergara, G | 2 |
| Del Greco, M | 1 |
| Bertoldi, A | 1 |
| Dallago, M | 1 |
| Soriano, J | 1 |
| Almendral, J | 1 |
| Arenal, A | 1 |
| San Román, D | 1 |
| Delcan, JL | 1 |
| Josephson, ME | 1 |
| Bigot, MC | 1 |
| Debruyne, D | 1 |
| Bonnefoy, L | 1 |
| Grollier, G | 1 |
| Moulin, M | 1 |
| Potier, JC | 1 |
| Braito, G | 1 |
| Santinelli, V | 2 |
| Turco, P | 2 |
| De Paola, M | 2 |
| Smimmo, D | 2 |
| Giasi, M | 1 |
| Santinelli, C | 1 |
| Chiariello, M | 2 |
| Condorelli, M | 1 |
| Montenero, AS | 1 |
| Natale, A | 1 |
| di Bona, G | 1 |
| Calvi, V | 1 |
| Santarelli, P | 1 |
| Manzoli, U | 1 |
| Vassiliadis, I | 1 |
| Papoutsakis, P | 1 |
| Kallikazaros, I | 1 |
| Stefanadis, C | 1 |
| Liusov, VA | 1 |
| Borodkin, VV | 1 |
| Volov, NA | 1 |
| Dudaev, VA | 1 |
| Kauffmann, R | 1 |
| Goich, J | 1 |
| Parra, C | 1 |
| Ayala, A | 1 |
| Manzur, F | 1 |
| Liguori, A | 1 |
| Pellegrino, G | 1 |
| Di Ieso, N | 1 |
| Piatto, A | 1 |
| Ruggiero, P | 1 |
| Scarnera, P | 1 |
| Guardascione, A | 1 |
| Zhang, S | 1 |
| Sun, RL | 2 |
| Song, YC | 2 |
| Boutaud, P | 1 |
| Guillem, JP | 1 |
| Maarek-Charbit, M | 1 |
| Amiel, A | 1 |
| Ciber, M | 1 |
| Herpin, D | 1 |
| Demange, J | 1 |
| Barbieri, O | 1 |
| Cammalleri, G | 1 |
| Gruttadauria, G | 1 |
| Rugiano, A | 1 |
| Vancheri, F | 1 |
| Fauchier, JP | 1 |
| Cosnay, P | 1 |
| Moquet, B | 1 |
| Rouesnel, P | 1 |
| Kapusta, P | 1 |
| Vrancea, F | 1 |
| Musto, B | 1 |
| D'Onofrio, A | 1 |
| Cavallaro, C | 1 |
| Musto, A | 1 |
| Allen, BJ | 1 |
| Brodsky, MA | 1 |
| Doria, R | 1 |
| Luckett, CR | 1 |
| Thomas, R | 1 |
| Henry, WL | 1 |
| Pu, JL | 1 |
| Madsen, JK | 1 |
| Nielsen, H | 1 |
| Madsen, BK | 1 |
| Dirix, LY | 1 |
| Moeremans, C | 1 |
| Fierens, H | 1 |
| Dielen, D | 1 |
| Vrints, C | 1 |
| Van Agt, E | 1 |
| Snoeck, J | 1 |
| Hammill, SC | 1 |
| McLaran, CJ | 1 |
| Wood, DL | 1 |
| Osborn, MJ | 1 |
| Gersh, BJ | 1 |
| Holmes, DR | 1 |
| Garson, A | 1 |
| Moak, JP | 1 |
| Smith, RT | 1 |
| Norton, JB | 1 |
| Shen, EN | 1 |
| Keung, E | 1 |
| Huycke, E | 1 |
| Dohrmann, ML | 1 |
| Nguyen, N | 1 |
| Morady, F | 1 |
| Sung, RJ | 1 |
| Beermann, J | 1 |
| Gerckens, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Randomized Study of Efficacy and Safety of 1c Class Antiarrhythmic Agent (Propafenone) in Septic Shock[NCT03029169] | Phase 4 | 210 participants (Actual) | Interventional | 2017-10-23 | Completed | ||
| [NCT00005237] | 0 participants | Observational | 1988-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for propafenone and Tachycardia, Supraventricular
| Article | Year |
|---|---|
Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia.
Topics: Ambulatory Care; Anti-Arrhythmia Agents; Cardiomyopathies; Flecainide; Hospitalization; Humans; Prop | 1994 |
Drug therapy of supraventricular tachyarrhythmias--based on efficacy or futility?
Topics: Atrial Fibrillation; Catheter Ablation; Chronic Disease; Humans; Propafenone; Tachycardia, Supravent | 1994 |
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
[Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Th | 1995 |
Propafenone: an effective agent for the management of supraventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Propafenone; Tachycardia, Supraventri | 1996 |
Placebo-controlled evaluations of propafenone for atrial tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Controlled Clinic | 1998 |
Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Propafenone; Research Design; Tachycardia, Supr | 1998 |
14 trials available for propafenone and Tachycardia, Supraventricular
| Article | Year |
|---|---|
Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Double-Blind Method; | 2019 |
[Efficacy of intravenous Acehytisine Hydrochloride versus propafenone on terminating paroxysmal supraventricular tachycardia: a double-blinded, randomized multi-center study].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Double-Blind Method; Drugs, Chinese Herbal; Female; | 2007 |
Action of ATP on ventricular automaticity.
Topics: Adenosine Triphosphate; Adrenergic beta-Antagonists; Ajmaline; Animals; Anti-Arrhythmia Agents; Aust | 1994 |
A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle A | 1995 |
Comparison of propafenone to atenolol for the prophylaxis of postcardiotomy supraventricular tachyarrhythmias: a prospective trial.
Topics: Adult; Aged; Atenolol; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; D | 1995 |
Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Res | 1995 |
Are there stereoselective electrophysiologic effects of intravenously administered (S)- or (R)-propafenone hydrochloride in patients with supraventricular tachycardia?
Topics: Adult; Aged; Electrocardiography; Female; Heart; Humans; Male; Middle Aged; Propafenone; Stereoisome | 1996 |
Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial | 1996 |
Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electroph | 1998 |
Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Double-Blind Method; Female; Humans; Male; Middl | 2001 |
Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Dose-Response Relationship, Drug; Female; Follo | 1991 |
Propafenone in Wolff-Parkinson-White syndrome at risk.
Topics: Administration, Oral; Adolescent; Adult; Atrial Fibrillation; Dose-Response Relationship, Drug; Fema | 1990 |
[Efficacy of propafenone in supraventricular arrhythmias].
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Electrocardiography; Female; Heart | 1989 |
Intravenous propafenone for termination of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, crossover study.
Topics: Adult; Aged; Double-Blind Method; Drug Evaluation; Electrocardiography; Humans; Injections, Intraven | 1986 |
51 other studies available for propafenone and Tachycardia, Supraventricular
| Article | Year |
|---|---|
Antiarrhythmic Medication in Neonates and Infants with Supraventricular Tachycardia.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Digoxin; Humans; Infant; Infant, Newborn; Propa | 2022 |
Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2023 |
The Wrong Drug That Led to the Right Diagnosis.
Topics: Action Potentials; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; D | 2019 |
Supraventricular tachyarrhythmias during the intrauterine, neonatal, and infant period: A 10-year population-based study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Incidence; Infant; Infant, Newborn; Male; Pregna | 2020 |
Propafenone for supraventricular arrhythmias in septic shock-Comparison to amiodarone and metoprolol.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Critical Care; Electric Countershock; Female; Humans; Male | 2017 |
Optimal sampling time and clinical implication of the SCN5A promoter haplotype in propafenone therapeutic drug monitoring.
Topics: Adult; Anti-Arrhythmia Agents; Drug Monitoring; Electrocardiography; Female; Haplotypes; Homozygote; | 2018 |
[Effectiveness of D,L-sotalol in post-ablative atrial arrhythmias in patients with atrial fibrillation treated with radiofrequency ablation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Catheter | 2009 |
[The efficacy of propafenon in the case of supraventricular atrioventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Drug Evaluation; Female; Humans; Male; Propafenone; Tachycardia, Paroxysmal; | 2010 |
Electrophysiological predictors of propafenone efficacy in prevention of atrioventricular nodal re-entrant and atrioventricular re-entrant tachycardia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrioventricular Node; Electrocardiography; Electrophysiologic | 2012 |
Preparation and evaluation of unitary doses of propafenone used in children with supraventricular tachycardia: a pilot study.
Topics: Anti-Arrhythmia Agents; Child; Humans; Pilot Projects; Propafenone; Tachycardia, Supraventricular | 2013 |
Paroxysmal supraventricular tachycardia induced by oral stimulation: a case report and review of swallow-induced dysrhythmias.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Deglutition; Electrocardiography; Humans; Male; Mastica | 2002 |
Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.
Topics: Adult; Anti-Arrhythmia Agents; Cyanosis; Dose-Response Relationship, Drug; Ebstein Anomaly; Echocard | 2003 |
[Psoriasis worsened by propafenone].
Topics: Aged; Anti-Arrhythmia Agents; Humans; Male; Propafenone; Psoriasis; Severity of Illness Index; Tachy | 2005 |
Broad complex tachycardia during treatment of atrial fibrillation with a 1c antiarrhythmic drug: ventricular or supraventricular proarrhythmia?
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Drug Thera | 2006 |
Clinical experience with propafenone for cardiac arrhythmias in the young.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Atrial Flutter; Cardiac Complexes, Premature | 1994 |
[Evaluation of the clinical acute electrophysiological effects of propafenone using transesophageal atrial pacing].
Topics: Adolescent; Adult; Aged; Cardiac Complexes, Premature; Cardiac Pacing, Artificial; Female; Humans; M | 1994 |
[Adenosine triphosphate for supraventricular tachycardia in newborns and suckling infants].
Topics: Adenosine Triphosphate; Digoxin; Drug Therapy, Combination; Echocardiography; Electrocardiography; E | 1994 |
[Propafenone efficacy in preventing supraventricular tachycardia in childhood].
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Evaluation; Echocardiography, Dopple | 1994 |
Oral propafenone as treatment for incessant supraventricular and ventricular tachycardia in children.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; | 1993 |
Reversible left ventricular diastolic dysfunction resulting from frequent supraventricular tachycardia.
Topics: Aged; Aged, 80 and over; Diastole; Echocardiography; Electrocardiography; Female; Humans; Propafenon | 1993 |
Current treatment options for paroxysmal supraventricular tachycardia.
Topics: Acute Disease; Catheter Ablation; Chronic Disease; Flecainide; Humans; Propafenone; Tachycardia, Atr | 1994 |
Usefulness of propafenone for supraventricular arrhythmias in infants and children.
Topics: Administration, Oral; Child; Child, Preschool; Drug Evaluation; Electrocardiography; Follow-Up Studi | 1993 |
The use of propafenone in the treatment of tachyarrhythmias in children.
Topics: Administration, Oral; Child, Preschool; Electrocardiography; Female; Humans; Injections, Intravenous | 1993 |
Comparison of mortality in patients treated with propafenone to those treated with a variety of antiarrhythmic drugs for supraventricular arrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Propafenone; Pr | 1993 |
Characteristics and management of chaotic atrial tachycardia of infancy.
Topics: Anti-Arrhythmia Agents; Electrocardiography, Ambulatory; Female; Fetal Diseases; Heart Defects, Cong | 1996 |
Behçet's disease and cardiac arrhythmia.
Topics: Adolescent; Anti-Arrhythmia Agents; Behcet Syndrome; Echocardiography, Doppler; Electrocardiography; | 1997 |
[Implantable event recorder: a new aid for the diagnosis of arrhythmogenic syncope].
Topics: Anti-Arrhythmia Agents; Atrial Premature Complexes; Digitalis Glycosides; Drug Eruptions; Electrocar | 1998 |
[The study of acute clinical electrophysiological effects of propafenone on paroxysmal supraventricular tachycardia using transesophageal atrial pacing technique].
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrioventricular Node; Cardiac Pacing, Artificial; Electr | 1997 |
[The emergency treatment of supraventricular tachyarrhythmias: the efficacy and safety of intravenous propafenone].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Drug Evaluation; Emergencies; F | 1992 |
Long-term follow-up of patients with inducible supraventricular tachycardia treated with flecainide or propafenone: therapy guided by transesophageal electropharmacologic testing.
Topics: Adult; Cardiac Pacing, Artificial; Female; Flecainide; Follow-Up Studies; Humans; Male; Propafenone; | 1992 |
Rate-dependent failure of ventricular capture in patients treated with oral propafenone.
Topics: Administration, Oral; Aged; Cardiac Pacing, Artificial; Electrocardiography; Heart Rate; Heart Ventr | 1992 |
Serum digoxin levels related to plasma propafenone levels during concomitant treatment.
Topics: Administration, Oral; Aged; Aged, 80 and over; Digoxin; Dose-Response Relationship, Drug; Drug Admin | 1991 |
Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Electrocardiography | 1991 |
[Electropharmacological test with class-I C drugs in paroxysmal supraventricular re-entrant tachycardia: is a negative result with a drug predictive of the ineffectiveness of other drugs of the same class?].
Topics: Adolescent; Adult; Cardiac Pacing, Artificial; Drug Evaluation; Electrocardiography; Female; Flecain | 1991 |
Opposite effects of propafenone and flecainide in a patient with reciprocating supraventricular tachycardia.
Topics: Administration, Oral; Cardiac Pacing, Artificial; Electrocardiography; Female; Flecainide; Follow-Up | 1990 |
Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Drug Administration Schedule; Echocardiography; Electrocardiography; Ele | 1990 |
[Use of prolecofen in the treatment of arrhythmia in patients with ischemic heart disease].
Topics: Adult; Aged; Atrial Fibrillation; Cardiac Complexes, Premature; Coronary Disease; Female; Hemostasis | 1989 |
[Use of propafenone in emergency therapy].
Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Drug Evaluation; Electrocardiograp | 1989 |
[Electrophysiologic effects of intravenous propafenone].
Topics: Adolescent; Adult; Electrocardiography; Electrophysiology; Female; Humans; Injections, Intravenous; | 1989 |
Paroxysmal supraventricular tachycardia: experience with propafenone.
Topics: Administration, Oral; Adult; Electrophysiology; Female; Humans; Infusions, Intravenous; Male; Middle | 1989 |
[Anti-arrhythmia efficacy of propafenone per os in the prevention of paroxysmal supraventricular arrhythmia resistant to class Ia agents].
Topics: Administration, Oral; Aged; Disopyramide; Drug Evaluation; Drug Resistance; Female; Humans; Male; Mi | 1989 |
[I.v. propafenone in supraventricular paroxysmal tachyarrhythmias in patients with Wolff-Parkinson-White syndrome. 2 clinical cases].
Topics: Adult; Atrial Fibrillation; Electrocardiography; Female; Humans; Infusions, Intravenous; Propafenone | 1988 |
[Injectable and oral propafenone in nodal reentry and pathways of ventricular preexcitation].
Topics: Administration, Oral; Adult; Aged; Electrocardiography; Female; Humans; Injections, Intravenous; Mal | 1986 |
Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia.
Topics: Cardiac Pacing, Artificial; Child; Electrocardiography; Electrophysiology; Female; Follow-Up Studies | 1988 |
Oral propafenone therapy for patients with paroxysmal supraventricular tachyarrhythmia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Female; Humans; Male; Mid | 1988 |
[Effects of intravenous propafenone on patients with supraventricular tachycardia evaluated with esophageal programmed electrical stimulation].
Topics: Adolescent; Adult; Aged; Electric Stimulation; Electrophysiology; Esophagus; Female; Humans; Injecti | 1988 |
[Propafenone. An antiarrhythmic agent for both ventricular and supraventricular arrhythmia].
Topics: Arrhythmias, Cardiac; Heart Ventricles; Humans; Propafenone; Tachycardia, Supraventricular | 1988 |
Symptomatic hyponatremia related to the use of propafenone.
Topics: Aged; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Propafenone; Tachycardia, Atrioventr | 1988 |
Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia.
Topics: Adult; Aged; Double-Blind Method; Female; Follow-Up Studies; Heart Conduction System; Hemodynamics; | 1987 |
Usefulness of intravenous propafenone for control of postoperative junctional ectopic tachycardia.
Topics: Child, Preschool; Heart Defects, Congenital; Heart Rate; Humans; Infant; Infant, Newborn; Injections | 1987 |
[Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle of His; Cardiomyopathy, Dilated; Coronary Diseas | 1986 |